The Safety and Clinical Efficacy of Human TRBC1 CAR-T Cell Therapy for Patients With Relapsed/Refractory TRBC1 Positive T Cell Hematological Maliganacies

Status: Suspended

Phase of Trial: Phase I

Latest Information Update: 30 Nov 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs AUTO-4 (Primary)
Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
Focus Adverse reactions

26 Nov 2023 Planned End Date changed from 1 Mar 2024 to 26 Nov 2023.
26 Nov 2023 Planned primary completion date changed from 1 Mar 2023 to 26 Nov 2023.
26 Nov 2023 Status changed from recruiting to suspended because qualified participants could not be enrolled.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com